PropertyValue
?:abstract
  • A screen by Kost-Alimova et al 1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI)
  • A screen by Kost-Alimova et al.1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
is ?:annotates of
?:creator
?:journal
  • Cell_Rep_Med
  • Cell_Reports_Medicine
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
?:type
?:who_covidence_id
  • #1065661
  • #926112
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/m7iikm6f>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/m7iikm6f>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all